Genmab A/S (GMAB) FinancialsGMABGenmab A/S

Genmab A/S (GMAB) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Royalties, accounting for 83.6% of total sales, equivalent to $966.00M. Other significant revenue streams include Net product sales and Collaboration revenue. Understanding this composition is critical for investors evaluating how GMAB navigates market cycles within the Biotechnology & Medical Research industry.

In the context of the broader market, GMAB competes directly with industry leaders such as GILD and MRNA. With a market capitalization of $22.75B, it holds a significant position in the sector. When comparing efficiency, GMAB's gross margin of N/A stands against GILD's 79.76% and MRNA's 64.14%. Such benchmarking helps identify whether Genmab A/S is trading at a premium or discount relative to its financial performance.

Genmab has shown strong financial performance, with total revenue of $1.155 billion in Q2 2026 and a net income of $303 million, indicating solid profitability. The gross margin remains high at 92.73%, reflecting the company's strong pricing power and operational efficiency.